ICMR’s Impact of Research and Innovation Scale (IRIS) – Measuring Biomedical Research Impact in India

Impact of Research and Innovation Scale

Impact of Research and Innovation Scale (IRIS) Latest News

  • The Indian Council of Medical Research (ICMR) has proposed the Impact of Research and Innovation Scale (IRIS) to measure the impact of biomedical, public health, and allied research projects.
  • Given ICMR’s role as India’s premier grants-giving and agenda-setting body in health research, IRIS could significantly shape the research ecosystem.

Key Features of IRIS

  • ICMR proposes to measure research impact in units called publication-equivalents (PEs)
  • A research paper published in a peer-reviewed journal that reports results or methods of primary research, or a systematic review and meta-analysis is assigned 1 PE.
  • While a research paper that is cited in policies or guidelines is assigned 10 PEs
  • A patent’s impact is 5 PEs and that of a commercial device being used at scale is 20 PEs.

Advantages of IRIS

  • Standardisation - Uniform metric: IRIS provides a common yardstick across disciplines (biochemistry, physiology, biomedical engineering, public health, etc).
  • Recognition beyond citations: Breaks the conventional citation-driven incentive system and encourages diverse forms of impactful research.
  • Policy and funding linkage: By tying PEs to funding allocation, IRIS can influence research prioritisation and resource distribution effectively.

Concerns and Limitations

  • Theoretical weakness:
    • PE assignment lacks strong theoretical rationale.
    • It excludes influential works. For example, commentary, perspective, and narratives review papers will have 0 PE.
    • In this case, the 1977 paper that introduced the biopsychosocial model of medicine, which transformed medical and public health research, will have no impact. 
    • Articulating new ideas and critical discourse around emerging evidence are at the foundation of research, yet the PE-based system could discourage Indian researchers from pursuing articles of this nature.
  • Skewed incentives:
    • It prioritises commercial devices (20 PEs) over policy-level interventions (10 PEs).
    • Risks undervaluing basic science, public health programmes, and academic medicine.
    • For example, the RATIONS clinical trial (studied nutrition in tuberculosis patients) and India’s Home-Based Neonatal Care (revolutionised community health programming) will be deemed to be less impactful.
  • Risk to research as a public good:
    • Over-commercialisation may erode the ethos of science as a public good.
    • Potential misuse in India’s already weak research ethics culture.
  • Need for transparency:
    • Development of IRIS requires rigorous methods, accountability, and peer validation.
    • Suggested approach
      • The assignment of PEs to different indicators could be done through a national-level Delphi study where researchers form a consensus on the assignment. 
      • Data must be shared with independent groups to analyse and validate the scale.

Conclusion

  • Measuring research impact is inherently complex, with no universally correct model.
  • ICMR must ensure transparency, inclusivity, and ethical safeguards while developing IRIS.
  • Balance is essential to incentivise innovation and translation into practice without undermining fundamental research and critical academic discourse.
  • Ultimately, research evaluation must align with India’s public health priorities and uphold research as a public good.

Source: TH

Impact of Research and Innovation Scale (IRIS) FAQs

Q1: What is the Impact of Research and Innovation Scale (IRIS) proposed by ICMR?

Ans: IRIS is a new framework that measures the impact of biomedical and health research using Publication-Equivalents (PEs) as the unit of assessment.

Q2: How does IRIS assign value to different types of research outputs?

Ans: Research papers = 1 PE, policy-cited research = 10 PEs, patents = 5 PEs, commercial devices in use = 20 PEs.

Q3: What are the advantages of introducing a standardised metric like IRIS?

Ans: It provides a uniform benchmark across disciplines, recognises impact beyond citations, and links research output with funding and policy decisions.

Q4: What are the key criticisms of IRIS as a research evaluation tool?

Ans: It may undervalue conceptual and foundational works, skew incentives towards commercialisation, and risk weakening the ethos of research as a public good.

Q5: What measures are suggested to ensure accountability and effectiveness of IRIS?

Ans: Adopting rigorous study design, national-level Delphi consensus, and independent validation mechanisms for assigning PE values.

India on U.S. Fentanyl Blacklist: Major’s List, Drug Trade, and U.S. Actions

Fentanyl Blacklist

Fentanyl Blacklist Latest News

  • In the latest Major’s List sent to the U.S. Congress, President Donald Trump identified 23 countries, including India, Pakistan, China, and Afghanistan, as major sources or transit hubs for illicit drugs, particularly fentanyl, posing a threat to the U.S. and its citizens.

Understanding the Major’s List

  • The Major’s List, compiled annually, identifies countries where geography, trade, or industry enable significant narcotics or precursor chemical flows into global markets. 
  • Inclusion does not reflect counternarcotics performance but highlights drug production or transit roles. 
  • However, nations like Afghanistan, Bolivia, Myanmar, Colombia, and Venezuela were flagged as having “failed demonstrably” in meeting international drug-control obligations.

Fentanyl: A Deadly Synthetic Opioid

  • Fentanyl, a synthetic opioid developed in the 1960s for severe medical pain relief, is now the leading cause of overdose deaths in the U.S. 
  • Illicit fentanyl is nearly 50 times stronger than heroin, with just 2 mg proving fatal by suppressing brainstem respiratory centres. 
  • Between August 2023 and August 2024, over 57,000 Americans died from opioid overdoses, mostly fentanyl-related. 
  • Though overdoses can be reversed with naloxone, rapid administration is crucial to prevent brain injury or death. 
  • In 2022, the U.S. DEA seized enough fentanyl for 379 million lethal doses — enough to kill the nation’s entire population.

Why Regulating Fentanyl Is Difficult

  • Unlike plant-based drugs like heroin or cocaine, fentanyl is lab-made using chemical precursors such as N-phenethyl-4-piperidone (NPP) and 4-anilino-N-phenethylpiperidine (4-ANPP)
  • These compounds have legitimate industrial and pharmaceutical uses, making regulation tricky. 
  • In counterfeit labs, traffickers can convert these precursors into fentanyl with basic glassware, solvents, and moderate heat, using common organic chemistry reactions. 
  • Since small amounts of precursors yield large fentanyl quantities and can be discreetly shipped, controlling their diversion into illicit networks has proven extremely challenging.

Fentanyl Supply Chain and U.S. Response

  • The fentanyl trade is a complex network. China and India produce key precursor chemicals, some of which are diverted into illicit markets. 
  • Mexican cartels process these into fentanyl powder, later pressed into counterfeit pills or mixed with other drugs, and smuggled into the U.S., mainly through the southwest border.

U.S. Legal and Trade Actions

  • The U.S. has pursued criminal prosecutions, trade penalties, and diplomatic pressure to curb trafficking. 
  • In January 2025, Indian firms Raxuter Chemicals and Athos Chemicals were charged with exporting fentanyl precursors. 
  • A senior executive of Raxuter was arrested in New York for smuggling. 
  • Following this, the U.S. Embassy in New Delhi revoked visas for business executives linked to trafficking.
  • In February 2025, the Trump administration imposed 25% tariffs on Canadian and Mexican imports and an additional 10% on Chinese imports, citing fentanyl trafficking. 
  • Tariffs on Canada and Mexico were suspended after stronger border enforcement, but those on China remain.

Domestic Enforcement and Public Health Measures

  • Within the U.S., the DEA has intensified seizures of fentanyl shipments, targeted trafficking networks, and intercepted counterfeit pills disguised as legitimate medicines. 
  • Simultaneously, naloxone distribution has been expanded, alongside public awareness campaigns warning against counterfeit drugs. 
  • Expanded treatment programmes aim to reduce demand and support recovery from opioid addiction.

Source: TH | IE | AJ

Fentanyl blacklist FAQs

Q1: What is the U.S. Major’s List in drug control?

Ans: It highlights countries linked to drug or precursor flows. Inclusion signals involvement in production or transit, not necessarily weak counternarcotics action.

Q2: Why has India been blacklisted on fentanyl?

Ans: India is cited as a source of precursor chemicals diverted into illicit channels. U.S. authorities have prosecuted Indian firms linked to fentanyl trafficking.

Q3: Why is fentanyl so dangerous compared to other opioids?

Ans: Illicit fentanyl is nearly 50 times stronger than heroin. Just 2 mg can be fatal, causing rapid respiratory depression and death without quick treatment.

Q4: Why is fentanyl regulation difficult globally?

Ans: Precursors like NPP and 4-ANPP have legitimate uses, but traffickers can easily convert them into fentanyl with basic lab equipment and ship discreetly.

Q5: How is the U.S. combating fentanyl trafficking?

Ans: The U.S. uses criminal prosecutions, trade tariffs, diplomatic pressure, DEA seizures, naloxone distribution, and awareness campaigns to fight fentanyl inflows and overdoses.

H-1B $100,000 Entry Fee: Impact, Exemptions, and Industry Challenges

H-1B Visa

H-1B Visa Latest News

  • The White House has introduced a $100,000 entry fee for H-1B visa holders starting September 21, 2025, causing concern among Indian tech workers and students, the largest H-1B user group. 
  • The fee applies only to new entrants to the US, while those already in the country extending or changing status are exempt.

H-1B $100,000 Entry Fee: What Changes, What’s Clear, and What’s Uncertain

  • From September 21, 2025, no H-1B petition for workers outside the US will be approved unless the sponsoring employer pays $100,000 upfront
  • Without proof of payment, consular stamping will be denied, blocking entry.

What Is Clear

  • The fee applies to all H-1B petitions for workers outside the US, including those needing consular stamping after travel. 
  • The Secretary of Homeland Security may waive the restriction for individuals, companies, or industries if deemed in the US national interest
  • The measure will last for 12 months, after which agencies will review it before the White House decides on an extension.

What Remains Uncertain

  • The proclamation does not clarify which sectors may qualify for waivers, though areas like healthcare, defence, and critical technology have historically been prioritised. 
  • It also leaves ambiguity over the treatment of universities and non-profits, which are usually cap-exempt under H-1B rules but are not explicitly excluded in this order.

Immigration Politics and the H-1B Debate in the US

  • Immigration has become one of the most divisive issues in US politics, rising from 2.1% in 2012 to 14.6% in 2024 as a top voter concern. 
  • Donald Trump’s rhetoric has consistently framed immigration — first low-skilled, now even skilled migration under the H-1B program — as a threat to American jobs and wages. 
  • This narrative, rooted in economic anxiety and racial undertones, portrays immigrants as displacing the struggling working class already burdened by unemployment, inflation, low wages, and housing crises
  • Trump and his camp now extend the same argument against H-1B workers, claiming they “steal” higher-paying tech jobs, echoing the themes of his earlier anti-immigrant campaigns.

Criticism of H-1B Visa

  • Nativist MAGA (Make America Great Again) Republicans argue that Indian workers are “stealing” American jobs and lowering wages. 
  • They claim H-1B visas, meant for top talent, are used by tech firms to hire mid-level staff at cheaper salaries
  • Critics point to the salary gap: in FY2023, 70% of approved petitions for Indians were under $100,000, below the US IT median salary of $104,420.

Industry Viewpoint

  • Industry leaders counter that H-1B visas are essential to fill America’s skills gap, especially in STEM fields. 
  • Data shows that China (3.57 million) and India (2.55 million) produce far more STEM graduates than the US (820,000), underlining the need for global talent.

India at the Epicentre of H-1B Impact

  • India, the largest user of the H-1B system with 71% of approvals in FY2024 (far ahead of China at 12–13%), faces the greatest disruption from the $100,000 entry fee. 
  • The new rule threatens the Optional Practical Training (OPT)-to-H-1B pathway for young Indian graduates, as employers may avoid the steep cost. 
  • Families already on H-1Bs risk travel-related disruptions. 
  • For India’s IT service firms and Global Capability Centres (GCCs), staff rotations to the US become prohibitively expensive, likely shifting more project work to offshore hubs like Bengaluru, Hyderabad, and Pune.

Industries Most Impacted by the H-1B $100,000 Fee

  • Big Tech and Cloud Firms - Amazon, with 12,000 approvals in early 2025, along with Microsoft, Meta, Google, and Apple, face massive cost hikes as each H-1B hire now costs $100,000 extra.
  • IT Service Providers - Indian majors like Infosys, TCS, Wipro, HCL and global firms like Cognizant, Capgemini, and IBM depend on H-1Bs for onsite delivery. The levy hits junior roles, central to their model.
  • Consulting and Finance - Firms such as JPMorgan Chase use H-1Bs for STEM and quantitative roles. The new surcharge significantly raises costs for these specialised hires.
  • Startups and Mid-Size Companies - With limited financial capacity, smaller firms are most vulnerable. Many will delay recruitment or offshore roles to avoid the fee burden.
  • Universities and Research Institutions - Postdoctoral researchers and specialist staff often rely on H-1Bs. Without exemptions, academic employers face unsustainable costs, affecting research and innovation.

Source: IE | IE | N18

H-1B Visa FAQs

Q1: What is the new H-1B $100,000 entry fee rule?

Ans: From September 21, 2025, U.S. employers must pay $100,000 upfront for petitions of H-1B workers outside the U.S., or entry will be denied.

Q2: Who is exempt from the H-1B $100,000 entry fee?

Ans: Workers already inside the U.S. extending or changing their status are exempt. Waivers may also apply if deemed in the national interest.

Q3: How long will the H-1B $100,000 fee rule last?

Ans: The rule is valid for 12 months initially. U.S. agencies will review its impact before the White House decides on extension or termination.

Q4: Why is India most affected by the H-1B $100,000 entry fee?

Ans: India accounts for over 70% of H-1B approvals. The new cost disrupts student-to-work transitions and IT firms reliant on staff rotations to the U.S.

Q5: Which industries are most impacted by the H-1B $100,000 levy?

Ans: Big Tech, IT services, consulting, finance, startups, and universities face higher costs, with offshore delivery likely to rise for Indian IT firms.

Isobutanol-Diesel Blending: India’s New Biofuel Experiment

Isobutanol-Diesel Blending

Isobutanol-Diesel Blending Latest News

  • India is exploring isobutanol-diesel blending as an alternative to ethanol, with a pilot project underway to assess its technical and economic feasibility.

Introduction

  • India is pushing forward in its biofuel journey, experimenting with new alternatives to conventional fossil fuels to meet its energy and climate goals. 
  • After ethanol blending with diesel proved technically unsuitable, the government and the Automotive Research Association of India (ARAI) have turned their attention to isobutanol, an alcohol-based compound with promising blending properties. 
  • Transport Minister Nitin Gadkari recently announced that India is working on pilot projects to evaluate the feasibility of isobutanol-diesel blending, which, if successful, could make India the first country to achieve this breakthrough.

Understanding Isobutanol and Its Properties

  • Isobutanol is a four-carbon alcohol widely used as a solvent in industries such as paints and chemicals. Its key attributes include:
    • Higher Flash Point: Less volatile and safer than ethanol, lowering fire risks.
    • Better Miscibility with Diesel: Compared with ethanol, isobutanol blends more effectively with diesel without requiring extensive chemical modifications.
    • Versatile Feedstock: Like ethanol, it can be produced from sugarcane syrup, molasses, and grains through microbial fermentation.
  • These properties make it technically more compatible with diesel engines than ethanol.

Why Ethanol Blending Failed with Diesel

  • Ethanol has been a cornerstone of India’s biofuel policy, especially in petrol blending, where the country has achieved 12% ethanol blending in 2023-24
  • However, blending ethanol with diesel faced hurdles:
    • Low Flash Point: Increased volatility and fire risk.
    • Poor Compatibility: Required chemical additives to stabilise the blend.
    • Engine Concerns: Blending caused ignition and combustion irregularities in diesel engines.
  • Thus, isobutanol emerged as a promising alternative for diesel blending.

Production and Economic Viability of Isobutanol

  • Isobutanol production follows a fermentation process similar to ethanol, but with specially engineered microbes that convert natural sugars into isobutanol. 
  • According to the Indian Sugar Mills Association (ISMA):
    • A sugar refinery with 150 kilo litres per day (klpd) capacity can produce 125 klpd ethanol and 20 klpd isobutanol with minor infrastructure modifications.
    • The use of surplus sugarcane and molasses, already abundant in India, provides a steady raw material supply.
  • However, the imbalance between rising cane prices and stagnant ethanol procurement prices poses an economic challenge that could extend to isobutanol production.

Technical and Performance Challenges

  • While isobutanol blends better with diesel than ethanol, experts highlight several technical considerations:
  • Cetane Number:
    • Isobutanol has a lower cetane number than diesel, which may reduce combustion efficiency.
    • This could cause engine knock, reduced power, and long-term damage.
  • Additives Requirement:
    • Cetane improvers would be needed, increasing costs.
    • Blending beyond 10% isobutanol is not advisable due to performance risks.
  • Emission Reduction Potential:
    • If optimised, the blend can reduce harmful emissions and support the import substitution of fossil fuels.

Pilot Project and Global Context

  • ARAI has initiated a pilot project, expected to take about 18 months, to study the impact of isobutanol-diesel blending across different vehicle classes. 
  • If India succeeds, it will become the first nation to commercialise this blend.
  • Globally, biofuel innovation has largely focused on ethanol, biodiesel, and advanced biofuels. 
  • India’s foray into isobutanol represents an effort to diversify its biofuel basket while reducing dependence on imported crude oil.

Source: TH

Isobutanol-Diesel Blending FAQs

Q1: Why is India exploring isobutanol-diesel blending?

Ans: India turned to isobutanol after ethanol blending with diesel failed due to volatility and engine issues.

Q2: What are the advantages of isobutanol over ethanol?

Ans: Isobutanol has a higher flash point, better miscibility with diesel, and safer blending properties.

Q3: How is isobutanol produced?

Ans: It is made from sugarcane syrup, molasses, or grains using engineered microbes through fermentation.

Q4: What challenges does isobutanol-diesel blending face?

Ans: Concerns include its lower cetane number, engine knock risk, and the need for additives.

Q5: When will the pilot project on isobutanol blending be completed?

Ans: The pilot project is expected to conclude in about 18 months.

Enquire Now